Citations

Showing 10 of 108152 citations.

Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity
Bansal, Aditya , Siegler, Elizabeth L. , Yang, Nan , Khadka, Roman H., Newsom, Alysha N., Hansen, Michael J. , Cox, Michelle J. , Roman, Claudia Manriquez , Schick, Kendall J. , Can, İsmail , Tapper, Erin E. , Nevala, Wendy K. , Fonkoua, Lionel Aurelien Kankeu , Horvei, Paulina , Ruff, Michael W. , Pandey, Mukesh K. , DeGrado, Timothy R. , Suksanpaisan, Lukkana , Peng, Kah-Whye , Sakemura, Reona , Siegler, Elizabeth L , Cox, Michelle J , Manriquez Roman, Claudia , Schick, Kendall J , Can, Ismail , Adada, Mohamad M, Bezerra, Evandro D. , Kankeu Fonkoua, Lionel Aurelien, Parikh, Sameer A , Kay, Neil E , Kenderian, Saad S. , Pandey, Mukesh K , Hefazi, Mehrdad , Adada, Mohamad M , Parikh, Sameer A. , Kay, Neil E.

Mayo Clinic

Cancer Immunology Research | July 9, 2021 | Volume: 9 | Issue: 9 | Pages: 1035-1046

10.1158/2326-6066.cir-20-0901 | PMID 34244299 Get It

Abstract Although chimeric antigen receptor T (CART)–cell therapy has been successful in treating certain hematologic malignancies, wider adoption of CART-cell therapy is limited because of minimal activity in solid tumors and development of life-threatening toxicities, including cytokine release syndrome (CRS). There is a lack of a robust, clinically relevant imaging platform to monitor in vivo expansion and trafficking to tumor sites. To address this, we utilized the sodium iodide symporter (NIS) as a platform to image and track CART cells. We engineered CD19-directed and B-cell maturation antigen (BCMA)–directed CART cells to express NIS (NIS+CART19 and NIS+BCMA-CART, respectively) and tested the sensitivity of 18F-TFB-PET to detect trafficking and expansion in systemic and localized tumor models and in a CART-cell toxicity model. NIS+CART19 and NIS+BCMA-CART cells were generated through dual transduction with two vectors and demonstrated exclusive 125I uptake in vitro. 18F-TFB-PET detected NIS+CART cells in vivo to a sensitivity level of 40,000 cells. 18F-TFB-PET confirmed NIS+BCMA-CART-cell trafficking to the tumor sites in localized and systemic tumor models. In a xenograft model for CART-cell toxicity, 18F-TFB-PET revealed significant systemic uptake, correlating with CART-cell in vivo expansion, cytokine production, and development of CRS-associated clinical symptoms. NIS provides a sensitive, clinically applicable platform for CART-cell imaging with PET scan. 18F-TFB-PET detected CART-cell trafficking to tumor sites and in vivo expansion, correlating with the development of clinical and laboratory markers of CRS. These studies demonstrate a noninvasive, clinically relevant method to assess CART-cell functions in vivo.
Educating Authors and Users of the Literature to Increase Vigilance of Predatory Publishing
Gerberi, Dana , Taylor, Julie M. , Beeler, Cynthia, Chelf, Cynthia , Chelf, Cynthia J , Taylor, Julie M.

Mayo Clinic

Journal of Hospital Librarianship | July 9, 2021 | Volume: 21 | Issue: 3 | Pages: 207-216

10.1080/15323269.2021.1942691 Get It

Radioembolization for Hepatocellular Carcinoma
Gündüz, Şeyda , Saini, Gia , Segaran, Nicole , Naidu, Sailen G., Patel, Indravadan , Alzubaidi, Sadeer , Öklü, Rahmi , Oklu, Rahmi , Naidu, Sailendra

Mayo Clinic

Digestive Disease Interventions | July 8, 2021 | Volume: 05 | Issue: 03 | Pages: 268-276

10.1055/s-0041-1732304 Get It

AbstractHepatocellular carcinoma (HCC) is the fastest-growing cancer worldwide, causing significant morbidity and mortality. Surgical resection, ablation, or transplantation is the best treatment option for patients with HCC. However, only about one-fifth of patients are suitable for such primary curative treatments due to underlying liver disease or rapid extension of the tumor. Image-guided locoregional therapies may prove an important alternative in this scenario, particularly transarterial radioembolization (TARE) with yttrium-90 (Y-90). Based on many studies, TARE can be considered a curative treatment option for patients with early-stage HCC, a bridge to transplantation, and a method for downstaging tumors to give patients with unresectable HCC a chance to potentially receive a curative treatment. TARE can be also combined with other treatment modalities to provide a better quality of life in patients when compared with systemic therapy in patients with unresectable HCC. Here, we discuss the use of TARE in the approach to HCC patients who are in early, intermediate, or advanced stages.
Response to the letter of Hoermann and colleagues
Peeters, Robin P. , Brito, Juan P. , Brito, Juan P

Mayo Clinic

European Journal of Endocrinology | July 8, 2021 | Volume: 185 | Issue: 3 | Pages: L7-L8

10.1530/eje-21-0677 | PMID 34243146 Get It

Editorial: thiopurines but not anti‐TNF monotherapy are linked to worse pregnancy outcomes in a large population‐based study
Kinnucan, Jami , Kane, Sunanda V. , Kane, S

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 8, 2021 | Volume: 54 | Issue: 3 | Pages: 343-344

10.1111/apt.16472 | PMID 34236094 Get It

LINKED CONTENTThis article is linked to Meyer et al paper. To view this article, visit https://doi.org/10.1111/apt.16448
Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
Semb, Anne Grete , Rollefstad, Silvia , Ikdahl, Eirik , Wibetoe, Grunde , Sexton, Joseph, Crowson, Cindy S., Riel, Piet L. C. M. van , González‐Gay, Miguel Á. , Sfikakis, Petros P. , Tektonidou, Maria G. , Lazarini, Argyro , Vassilopoulos, Dimitrios , Kuriya, Bindee , Durez, Patrick , Pascual‐Ramos, Virginia , Galarza-Delgado, D. Á. , Misra, Durga Prasanna , Borg, Andrew , Mu, Rong , Мirrakhimov, Erkin М , Gheta, Diane, Douglas, Karen, Agarwal, Vikas , Myasoedova, S. Е. , Krougly, Lev B. , Tuchyňová, Alena, Tomčík, Michal , Laštůvka, Jiří, Hořák, Pavel , Medková, Helena, Kerola, Anne M , Crowson, Cindy, Karpouzas, George Athanasios , Gonzalez-Gay, Miguel A , Tektonidou, Maria G , Durez, Patrick , Pascual-Ramos, Virginia , Galarza-Delgado, Dionicio Angel , Misra, Durga Prasanna , Agarwal, Vikas , Valentinovna Popkova, Tatiana , Semb, Anne Grete , Kitas, George D. , Graham, Ian , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , Myasoedova, Elena , Hitchon, Carol , Stoenoiu, Maria Simona , Faggiano, Pompilio Massimo , Vrablı́k, Michal

Mayo Clinic

RMD Open | July 8, 2021 | Volume: 7 | Issue: 2 | Pages: e001724

10.1136/rmdopen-2021-001724 | PMID 34244381 Get It

Aim The objective was to examine the prevalence of atherosclerotic cardiovascular disease (ASCVD) and its risk factors among patients with RA with diabetes mellitus (RA-DM) and patients with RA without diabetes mellitus (RAwoDM), and to evaluate lipid and blood pressure (BP) goal attainment in RA-DM and RAwoDM in primary and secondary prevention. Methods The cohort was derived from the Survey of Cardiovascular Disease Risk Factors in Patients with Rheumatoid Arthritis from 53 centres/19 countries/3 continents during 2014–2019. We evaluated the prevalence of cardiovascular disease (CVD) among RA-DM and RAwoDM. The study population was divided into those with and without ASCVD, and within these groups we compared risk factors and CVD preventive treatment between RA-DM and RAwoDM. Results The study population comprised of 10 543 patients with RA, of whom 1381 (13%) had DM. ASCVD was present in 26.7% in RA-DM compared with 11.6% RAwoDM (p<0.001). The proportion of patients with a diagnosis of hypertension, hyperlipidaemia and use of lipid-lowering or antihypertensive agents was higher among RA-DM than RAwoDM (p<0.001 for all). The majority of patients with ASCVD did not reach the lipid goal of low-density lipoprotein cholesterol <1.8 mmol/L. The lipid goal attainment was statistically and clinically significantly higher in RA-DM compared with RAwoDM both for patients with and without ASCVD. The systolic BP target of <140 mm Hg was reached by the majority of patients, and there were no statistically nor clinically significant differences in attainment of BP targets between RA-DM and RAwoDM. Conclusion CVD preventive medication use and prevalence of ASCVD were higher in RA-DM than in RAwoDM, and lipid goals were also more frequently obtained in RA-DM. Lessons may be learnt from CVD prevention programmes in DM to clinically benefit patients with RA .
Endarterectomy for symptomatic non-stenotic carotids: a systematic review and descriptive analysis
Larson, Anthony S. , Nardi, Valentina , Brinjikji, Waleed , Larson, Anthony , Benson, John C. , Savastano, Luis , Nardi, Valentina , Lanzino, Giuseppe

Mayo Clinic

Stroke and Vascular Neurology | July 8, 2021 | Volume: 7 | Issue: 1 | Pages: e001122

10.1136/svn-2021-001122 | PMID 34244446 Get It

Objective To systematically analyse prior reports of carotid endarterectomy (CEA) performed in cases of ≤50% carotid stenosis in order to understand patient tolerance and potential benefit. Methods A systematic review and descriptive analysis was performed in concordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. An English-language search was performed of online databases using librarian-selected search terms. Abstracts were reviewed for relevance which included mention of carotid endarterectomy and stenosis. Prospective or retrospective observational cohort studies that reported series of patients who underwent endarterectomy for minimal (≤50%) luminal stenosis with reported outcomes were included. Results Six studies (which included our institutional series) with a total of 143 patients met the inclusion criteria. The weighted mean age at the time of CEA was 72.3 years; 113 (79.0%) were male. 55.8% of patients with available data had recurrent ipsilateral ischaemic events despite medical therapy. Two patients out of 129 with available perioperative data (1.6%) had perioperative MRI findings of acute ischaemic stroke, both within the hemisphere contralateral to the side of CEA. Of the 138 patients with available follow-up (mean, 36 months), none had recurrent ipsilateral ischaemic events. Conclusions Endarterectomy for symptomatic carotid disease causing ≤50% stenosis may be a potentially beneficial strategy to prevent stroke recurrence. Studies with robust methodology are needed to draw more definitive conclusions in terms of the safety and efficacy of endarterectomy for minimal stenosis with vulnerable features relative to intensive medical therapy.
Echocardiography, lung ultrasound, and cardiac magnetic resonance findings in COVID‐19: A systematic review
Barssoum, Kirolos , Victor, Varun , Kumar, Ashish , Mubasher, Mahmood , Hassib, Mohab, Magdi, Mohamed, Renjithlal, Sarathlal, Abdelazeem, Mohamed , Shariff, Mariam , Idemudia, Osarenren , Ibrahim, Mounir , Mohamed, Amr , Patel, Harsh , Diab, Mohamed , Szeles, Andras , Ibrahim, Fadi , Jha, Roshan Kumar , Akula, Navya, Nanda, Navin C. , Kumar, Ashish , Kumar, Ashish , Shariff, Mariam , Chowdhury, Medhat , Salem, Ahmad, Thakkar, Samarthkumar , Kalra, Ankur

Mayo Clinic

Echocardiography | July 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/echo.15152 | PMID 34236091 Get It

Second Primary Tumors in Patients Presenting With Unilateral HPV‐Associated Tonsillar Squamous Cell Carcinoma
McMillan, Ryan A. , Abel, Kathryn M. Van , Routman, David M. , Wittich, Michelle A. Neben, Kasperbauer, Jan L. , Price, Katharine R., Moore, Eric J. , Van Abel, Kathryn M , Yin, Linda X , Routman, David M , Neben Wittich, Michelle A, Kasperbauer, Jan , Moore, Eric J , McMillan, Ryan A , Yin, Linda X. , Daniel, J. , Price, Daniel L. , Chintakuntlawar, Ashish V.

Mayo Clinic

The Laryngoscope | July 8, 2021 | Volume: 132 | Issue: 2 | Pages: 332-338

10.1002/lary.29741 | PMID 34236086 Get It

ObjectiveTo describe and compare rates of metachronous and synchronous second primaries of the contralateral tonsil in patients with primary HPV(+) tonsillar squamous cell carcinoma (SCC).Study DesignRetrospective cohort study.Materials and MethodsThis is a single tertiary care center retrospective case series, from 2006 to 2019, of HPV(+) tonsillar SCC patients who underwent primary surgical resection with unilateral wide‐field tonsillectomy or bilateral tonsillectomy for diagnostic or therapeutic purposes. A metachronous second primary is one diagnosed >6 months after completion of surgical treatment. A synchronous second primary is one diagnosed during bilateral tonsillectomy for unilateral HPV(+) tonsillar SCC. Rates of second primary and patient characteristics were compared using chi‐square tests.ResultsAbout 303 patients underwent unilateral surgical resection +/− adjuvant therapy for HPV(+) tonsillar SCC. One (0.3%) developed a metachronous second primary in the contralateral tonsil 11.9 years following treatment. Fifty‐seven patients with HPV(+) tonsillar SCC underwent bilateral tonsillectomy, and 37/57 (65%) had no clinical signs for contralateral disease. Of these, only 1/37 (2.7%) was incidentally found to have a synchronous second primary. Twenty patients underwent bilateral tonsillectomy due to clinical concern for contralateral disease. Of these, 3/20 (15%) were found to have a synchronous HPV(+) SCC in the contralateral tonsil.ConclusionsThe prevalence of metachronous second primary after appropriate treatment of HPV(+) tonsillar SCC is very low (0.3%) and so is the chance of incidentally discovering a synchronous second primary during bilateral tonsillectomy (2.7%). We do not recommend bilateral tonsillectomy as a part of the routine algorithm in the surgical management of these patients.Level of Evidence3 Laryngoscope, 132:332–338, 2022